{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:39:20Z","timestamp":1792589960375,"version":"4.5.0"},"reference-count":45,"publisher":"MyJove Corporation","issue":"231","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/70988","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T23:02:07Z","timestamp":1779058927000},"source":"Crossref","is-referenced-by-count":1,"title":["A Treatment and Monitoring Protocol for Tocilizumab in Refractory Macrophage Activation Syndrome with Systemic Juvenile Idiopathic Arthritis"],"prefix":"10.3791","author":[{"given":"Xueping","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"ref1","first-page":"9323141","type":"journal-article","article-title":"Allogeneic hematopoietic cell transplant for systemic juvenile idiopathic arthritis and macrophage activation syndrome","volume":"2021","author":"Davidson","year":"2021","unstructured":"Davidson N, et al. Allogeneic hematopoietic cell transplant for systemic juvenile idiopathic arthritis and macrophage activation syndrome. Case Rep Rheumatol. 2021;2021:9323141.","journal-title":"Case Rep Rheumatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1123104","DOI":"10.3389\/fped.2023.1123104","type":"journal-article","article-title":"Case report: emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome","volume":"11","author":"Chellapandian","year":"2023","unstructured":"Chellapandian D, Milojevic D. Case report: emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. Front Pediatr. 2023;11:1123104.","journal-title":"Front Pediatr"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/children11070755","type":"journal-article","article-title":"Macrophage activation syndrome in children: update on diagnosis and treatment","volume":"11","author":"Lee","year":"2024","unstructured":"Lee J, et al. Macrophage activation syndrome in children: update on diagnosis and treatment. Children. 2024;11(7):755.","journal-title":"Children"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/ard-2023-224123","type":"journal-article","article-title":"The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS)","volume":"82","author":"Shakoory","year":"2023","unstructured":"Shakoory B, et al. The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS). Ann Rheum Dis. 2023;82(10):1271-85.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"ref5","first-page":"e46083","type":"journal-article","article-title":"Prolonged fever in a pediatric patient: a case of systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome","volume":"15","author":"Cortes","year":"2023","unstructured":"Cortes M, Nudelman BG, Rouse MJ, Frost MD. Prolonged fever in a pediatric patient: a case of systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. Cureus. 2023;15(9):e46083.","journal-title":"Cureus"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1136\/ard-2024-225851","type":"journal-article","article-title":"EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease","volume":"83","author":"Fautrel","year":"2024","unstructured":"Fautrel B, et al. EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. Ann Rheum Dis. 2024;83(12):1614-27.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/rheumatology\/keae391","type":"journal-article","article-title":"Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project","volume":"64","author":"Baldo","year":"2025","unstructured":"Baldo F, et al. Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project. Rheumatology (Oxford). 2025;64(1):32-44.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s10067-025-07420-0","type":"journal-article","article-title":"Characterization of patients with macrophage activation syndrome secondary to systemic juvenile idiopathic arthritis","volume":"44","author":"Rogowska","year":"2025","unstructured":"Rogowska J, et al. Characterization of patients with macrophage activation syndrome secondary to systemic juvenile idiopathic arthritis. Clin Rheumatol. 2025;44(5):2023-29.","journal-title":"Clin Rheumatol"},{"key":"ref9","first-page":"1811","type":"journal-article","article-title":"Emapalumab in macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"382","author":"De Benedetti","year":"2020","unstructured":"De Benedetti F, et al. Emapalumab in macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. N Engl J Med. 2020;382:1811-22.","journal-title":"N Engl J Med"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.46497\/ArchRheumatol.2021.7953","type":"journal-article","article-title":"Biologics in juvenile idiopathic arthritis: main advantages and major challenges","volume":"36","author":"Adrovic","year":"2021","unstructured":"Adrovic A, et al. Biologics in juvenile idiopathic arthritis: main advantages and major challenges. Arch Rheumatol. 2021;36(1):146-57.","journal-title":"Arch Rheumatol"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/24725625.2020.1818961","type":"journal-article","article-title":"Reintroduction of tocilizumab elicited macrophage activation syndrome in a patient with adult-onset Still\u2019s disease with a previous successful tocilizumab treatment","volume":"5","author":"Naniwa","year":"2021","unstructured":"Naniwa T, Uehara K, Yamabe T, Ohmura SI. Reintroduction of tocilizumab elicited macrophage activation syndrome in a patient with adult-onset Still\u2019s disease with a previous successful tocilizumab treatment. Mod Rheumatol Case Rep. 2021;5(2):360-64.","journal-title":"Mod Rheumatol Case Rep"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/14397595.2021.1899565","type":"journal-article","article-title":"Macrophage activation syndrome in patients with adult-onset Still\u2019s disease under tocilizumab treatment: a single-center observational study","volume":"32","author":"Yamabe","year":"2021","unstructured":"Yamabe T, Ohmura SI, Uehara K, Naniwa T. Macrophage activation syndrome in patients with adult-onset Still\u2019s disease under tocilizumab treatment: a single-center observational study. Mod Rheumatol. 2021;32(1):169-76.","journal-title":"Mod Rheumatol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1002\/art.38472","type":"journal-article","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab","volume":"66","author":"Ravelli","year":"2014","unstructured":"Ravelli A, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. Arthritis Rheumatol. 2014;66:S83-S84.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cyto.2012.02.006","type":"journal-article","article-title":"Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6","volume":"58","author":"Shimizu","year":"2012","unstructured":"Shimizu M, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58(2):287-94.","journal-title":"Cytokine"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1604648","DOI":"10.3389\/fimmu.2025.1604648","type":"journal-article","article-title":"Efficacy and safety of ruxolitinib in adult patients with refractory rheumatic disease-associated macrophage activation syndrome","volume":"16","author":"Li","year":"2025","unstructured":"Li J, et al. Efficacy and safety of ruxolitinib in adult patients with refractory rheumatic disease-associated macrophage activation syndrome. Front Immunol. 2025;16:1604648.","journal-title":"Front Immunol"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1007\/s10067-024-07126-9","type":"journal-article","article-title":"Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial","volume":"43","author":"Li","year":"2024","unstructured":"Li C, et al. Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial. Clin Rheumatol. 2024;43(11):3457-67.","journal-title":"Clin Rheumatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"894846","DOI":"10.3389\/fped.2022.894846","type":"journal-article","article-title":"Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis","volume":"10","author":"Kostik","year":"2022","unstructured":"Kostik MM, et al. Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis. Front Pediatr. 2022;10:894846.","journal-title":"Front Pediatr"},{"issue":"9","key":"ref18","doi-asserted-by":"crossref","first-page":"e29102","DOI":"10.1002\/pbc.29102","type":"journal-article","article-title":"Continuous intravenous anakinra for treating severe secondary haemophagocytic lymphohistiocytosis\/macrophage activation syndrome in critically ill children","volume":"68","author":"Charlesworth","year":"2021","unstructured":"Charlesworth JEG, et al. Continuous intravenous anakinra for treating severe secondary haemophagocytic lymphohistiocytosis\/macrophage activation syndrome in critically ill children. Pediatr Blood Cancer. 2021;68(9):e29102.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/rheumatology\/keae440","type":"journal-article","article-title":"Long-term efficacy of MAS825, a bispecific anti-IL-1\u03b2 and IL-18 monoclonal antibody, in two patients with systemic JIA and recurrent episodes of macrophage activation syndrome","volume":"64","author":"Caorsi","year":"2024","unstructured":"Caorsi R, et al. Long-term efficacy of MAS825, a bispecific anti-IL-1\u03b2 and IL-18 monoclonal antibody, in two patients with systemic JIA and recurrent episodes of macrophage activation syndrome. Rheumatology (Oxford). 2024;64(3):1528-33.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/s10165-003-0259-0","type":"journal-article","article-title":"Inflammatory cytokines and systemic-onset juvenile idiopathic arthritis","volume":"14","author":"Yokota","year":"2004","unstructured":"Yokota S, et al. Inflammatory cytokines and systemic-onset juvenile idiopathic arthritis. Mod Rheumatol. 2004;14(1):12-17.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/art.39332","type":"journal-article","article-title":"2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"68","author":"Ravelli","year":"2016","unstructured":"Ravelli A, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2016;68(3):566-76.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/acr2.11048","type":"journal-article","article-title":"Ferritin to erythrocyte sedimentation rate ratio: simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"1","author":"Eloseily","year":"2019","unstructured":"Eloseily EMA, et al. Ferritin to erythrocyte sedimentation rate ratio: simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic arthritis. ACR Open Rheumatol. 2019;1(6):345-49.","journal-title":"ACR Open Rheumatol"},{"issue":"12","key":"ref23","first-page":"969","type":"journal-article","article-title":"Expert consensus on the diagnosis and treatment of systemic juvenile idiopathic arthritis (2019 edition)","volume":"34","author":"Zhou","year":"2019","unstructured":"Zhou W, Li J, Tang XM, et al. Expert consensus on the diagnosis and treatment of systemic juvenile idiopathic arthritis (2019 edition). Chin J Pract Pediatr. 2019;34(12):969-76.","journal-title":"Chin J Pract Pediatr"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/rheumatology\/keaa240","type":"journal-article","article-title":"Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis","volume":"59","author":"Tibaldi","year":"2020","unstructured":"Tibaldi J, et al. Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2020;59(11):3505-14.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12969-016-0085-5","type":"journal-article","article-title":"Clinical outcome measures in juvenile idiopathic arthritis","volume":"14","author":"Consolaro","year":"2016","unstructured":"Consolaro A, et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2016;14(1):23.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"9","key":"ref26","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3390\/children12091193","type":"journal-article","article-title":"Hyperferritinemia and Macrophage Activation Syndrome in Septic Shock: Recent Advances with a Pediatric Focus","volume":"12","author":"Briassouli","year":"2025","unstructured":"Briassouli E, Syrimi N, Ilia S. Hyperferritinemia and Macrophage Activation Syndrome in Septic Shock: Recent Advances with a Pediatric Focus. Children. 2025;12(9):1193.","journal-title":"Children"},{"issue":"Suppl 2","key":"ref27","doi-asserted-by":"crossref","first-page":"Si167","DOI":"10.1093\/rheumatology\/keae124","type":"journal-article","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or -6 therapy","volume":"63","author":"Ulu","year":"2024","unstructured":"Ulu K, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or -6 therapy. Rheumatology (Oxford). 2024;63(Suppl 2):Si167-Si172.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/art.20198","type":"journal-article","article-title":"Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis","volume":"50","author":"Grom","year":"2004","unstructured":"Grom AA. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum. 2004;50(3):689-98.","journal-title":"Arthritis Rheum"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejim.2020.10.020","type":"journal-article","article-title":"Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19","volume":"83","author":"Di Nisio","year":"2021","unstructured":"Di Nisio M, et al. Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19. Eur J Intern Med. 2021;83:34-38.","journal-title":"Eur J Intern Med"},{"issue":"8","key":"ref30","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/rheumatology\/keu524","type":"journal-article","article-title":"Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-\u03b3","volume":"54","author":"Put","year":"2015","unstructured":"Put K, et al. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-\u03b3. Rheumatology (Oxford). 2015;54(8):1507-17.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"ref31","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","type":"journal-article","article-title":"Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with emphasis on interleukin-18","volume":"49","author":"Shimizu","year":"2010","unstructured":"Shimizu M, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with emphasis on interleukin-18. Rheumatology (Oxford). 2010;49(9):1645-53.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"ref32","doi-asserted-by":"crossref","first-page":"rkaa054.003","DOI":"10.1093\/rap\/rkaa054.003","type":"journal-article","article-title":"Recognition of subclinical macrophage activation syndrome in an adolescent systemic juvenile idiopathic arthritis patient receiving tocilizumab","volume":"4","author":"Ng","year":"2020","unstructured":"Ng S, et al. Recognition of subclinical macrophage activation syndrome in an adolescent systemic juvenile idiopathic arthritis patient receiving tocilizumab. Rheumatol Adv Pract. 2020;4(Suppl 1):rkaa054.003.","journal-title":"Rheumatol Adv Pract"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3899\/jrheum.140288","type":"journal-article","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab","volume":"42","author":"Yokota","year":"2015","unstructured":"Yokota S, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol. 2015;42(4):712-22.","journal-title":"J Rheumatol"},{"issue":"7","key":"ref34","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1111\/ajt.16459","type":"journal-article","article-title":"Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation","volume":"21","author":"Chandran","year":"2021","unstructured":"Chandran S, et al. Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation. Am J Transplant. 2021;21(7):2543-54.","journal-title":"Am J Transplant"},{"issue":"21","key":"ref35","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.3390\/ijms20215293","type":"journal-article","article-title":"Immunobiology of atherosclerosis: a complex network of interactions","volume":"20","author":"Herrero-Fernandez","year":"2019","unstructured":"Herrero-Fernandez B, Gomez-Bris R, Somovilla-Crespo B, Gonzalez-Granado JM. Immunobiology of atherosclerosis: a complex network of interactions. Int J Mol Sci. 2019;20(21):5293.","journal-title":"Int J Mol Sci"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"871592","DOI":"10.3389\/fimmu.2022.871592","type":"journal-article","article-title":"Role of tocilizumab in downregulating sCD163 plasmatic levels in a cohort of COVID-19 patients","volume":"13","author":"Marocco","year":"2022","unstructured":"Marocco R, et al. Role of tocilizumab in downregulating sCD163 plasmatic levels in a cohort of COVID-19 patients. Front Immunol. 2022;13:871592.","journal-title":"Front Immunol"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jaci.2021.05.002","type":"journal-article","article-title":"Neutralizing anti-IL-1 receptor antagonist autoantibodies induce inflammatory and fibrotic mediators in IgG4-related disease","volume":"149","author":"Jarrell","year":"2022","unstructured":"Jarrell JA, et al. Neutralizing anti-IL-1 receptor antagonist autoantibodies induce inflammatory and fibrotic mediators in IgG4-related disease. J Allergy Clin Immunol. 2022;149(1):358-68.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"ref38","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.berh.2009.08.003","type":"journal-article","article-title":"Systemic JIA: new developments in pathophysiology and therapy","volume":"23","author":"Vastert","year":"2009","unstructured":"Vastert SJ, Kuis W, Grom AA. Systemic JIA: new developments in pathophysiology and therapy. Best Pract Res Clin Rheumatol. 2009;23(5):655-64.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"ref39","first-page":"142","type":"journal-article","article-title":"Recommendations for diagnosis and treatment of juvenile idiopathic arthritis in China","volume":"61","author":"Li","year":"2022","unstructured":"Li CF, et al. Recommendations for diagnosis and treatment of juvenile idiopathic arthritis in China. Zhonghua Nei Ke Za Zhi. 2022;61(2):142-56.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"6","key":"ref40","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/art.38615","type":"journal-article","article-title":"Is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?","volume":"66","author":"Nigrovic","year":"2014","unstructured":"Nigrovic PA. Is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2014;66(6):1405-13.","journal-title":"Arthritis Rheumatol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"665028","DOI":"10.3389\/fmed.2021.665028","type":"journal-article","article-title":"Short-term outcomes and predictors of effectiveness of tocilizumab in systemic juvenile idiopathic arthritis","volume":"8","author":"Nada","year":"2021","unstructured":"Nada DW, et al. Short-term outcomes and predictors of effectiveness of tocilizumab in systemic juvenile idiopathic arthritis. Front Med (Lausanne). 2021;8:665028.","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"ref42","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1007\/s10067-018-4297-6","type":"journal-article","article-title":"Impact of biologics on disease course in systemic-onset juvenile idiopathic arthritis","volume":"37","author":"Baris","year":"2018","unstructured":"Baris HE, Anderson E, Sozeri B, Dedeoglu F. Impact of biologics on disease course in systemic-onset juvenile idiopathic arthritis. Clin Rheumatol. 2018;37(12):3263-73.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"ref43","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/1756-185X.13649","type":"journal-article","article-title":"Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients","volume":"22","author":"Barut","year":"2019","unstructured":"Barut K, et al. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients. Int J Rheum Dis. 2019;22(9):1661-69.","journal-title":"Int J Rheum Dis"},{"issue":"25","key":"ref44","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","type":"journal-article","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","unstructured":"De Benedetti F, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385-95.","journal-title":"N Engl J Med"},{"issue":"3","key":"ref45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","type":"journal-article","article-title":"Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis","volume":"77","author":"Nakaoka","year":"2018","unstructured":"Nakaoka Y, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis. Ann Rheum Dis. 2018;77(3):348-54.","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/70988\/a-treatment-monitoring-protocol-for-tocilizumab-refractory-macrophage","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:47:19Z","timestamp":1792586839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/70988\/a-treatment-monitoring-protocol-for-tocilizumab-refractory-macrophage"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":45,"journal-issue":{"issue":"231","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3791\/70988","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}